Answers are grounded in this paper and cite their sources.
A subcutaneous implantable cardioverter defibrillator (S-ICD) is a validated alternative to a transvenous ICD for patients without pacing indications. However, limited data exist regarding its safety and efficacy in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). A 21-year-old man was referred after a syncope during a sport event. A 12-lead electrocardiogram showed repolarization abnormalities, and cardiac magnetic resonance demonstrated right ventricular dilatation, biventricular dysfunction, and fibrosis compatible with a diagnosis of ARVC. An S-ICD was implanted after successful preimplant screening. Genetic testing identified a known pathogenic plakophilin-2 variant. The patient received an S-ICD. At 18 months, lead noise, undersensing, and oversensing occurred because of reduced QRS amplitude. Imaging confirmed disease progression. The S-ICD was explanted and replaced by a transvenous ICD. The patient was referred for heart transplant evaluation. Our case represents a phenotype variant of ARVC with failure of the S-ICD system due to a temporal change in QRS amplitude over a short period of time. Advanced discrimination algorithms on the S-ICD may not be sufficient to prevent device failure. Cardiac magnetic resonance and genetic testing could eventually play a major role in the selection of a device in patients with ARVC. This case illustrates S-ICD failure associated with rapidly progressive ARVC, underscoring the need for close follow-up and tailored device selection in this population.
No takes yet. Share an insight, caveat, or question.
Cinq‐Mars et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: